Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Wenying Yang, Juan Du, Minlu Zhang, Jing Hou, Xia Zhang & Nan Cui. (2022) Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study. Current Medical Research and Opinion 38:11, pages 1807-1814.
Read now
Read now
Deep Dutta, Deepak Khandelwal & Sanjay Kalra. (2020) Injectable combination therapies for the management of diabetes: an Indian perspective. Expert Opinion on Drug Metabolism & Toxicology 16:3, pages 209-216.
Read now
Read now
G. Lozano-Ortega, S. Goring, H.A. Bennett, K. Bergenheim, C. Sternhufvud & J. Mukherjee. (2016) Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Current Medical Research and Opinion 32:5, pages 807-816.
Read now
Read now
Stuart Samuel, Devesh Goswami, Kenny Shum, Kristina S. Boye, Badri Rengarajan, Bradley Curtis & Sarah E. Curtis. (2015) A model of mild hypoglycemia. Current Medical Research and Opinion 31:4, pages 633-641.
Read now
Read now
Wenying Yang, Xiangjin Xu, Xiaomin Liu, Gangyi Yang, Yutaka Seino, Henning Andersen & Hideaki Jinnouchi. (2013) Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes. Current Medical Research and Opinion 29:12, pages 1599-1608.
Read now
Read now
Paul Valensi, Joseph Shaban, Marian Benroubi, Ryuzo Kawamori, Vito Borzì, Siddharth Shah, Yang Wenying, Vinay Prusty, Jes B. Hansen & Janusz Gumprecht. (2013) Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study. Current Medical Research and Opinion 29:6, pages 601-609.
Read now
Read now
Katherine Esposito & Dario Giugliano. (2012) Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opinion on Biological Therapy 12:2, pages 209-221.
Read now
Read now
Articles from other publishers (51)
Bipin Sethi, A. G. Unnikrishnan, Vageesh Ayyar, P. K. Jabbar, K. K. Ganguly, Sudhir Bhandari, Ashu Rastogi, Rajarshi Mukherjee, Vivek Sundaram & Adlyne R. Asirvatham. (2022) Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus. Diabetes Therapy 13:8, pages 1409-1481.
Crossref
Crossref
Peng Men, Shuli Qu, Zhenqiang Song, Yanjun Liu, Chaoyun Li & Suodi Zhai. (2020) Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis. Diabetes Therapy 11:8, pages 1745-1755.
Crossref
Crossref
Jianping Weng, Jiajun Zhao, Zhiguang Zhou, Xiaohui Guo, Dajin Zou, Qiuhe Ji, Nanwei Tong, Qifu Li, Jun Zhu, Qiang Li, Guijun Qin, Ping Feng, Liyong Yang, Zhengnan Gao, Lulu Chen, Hong Li, Yiming Li, Longyi Zeng, Dalong Zhu, Juming Lu, Tianhong Luo & Nan Cui. (2019) Observational study evaluating the effectiveness of physician‐targeted education for improving glycemic management of patients with type 2 diabetes (BEYOND II). Journal of Diabetes 12:1, pages 66-76.
Crossref
Crossref
H. Iraqi, H. Jamoussi Kamoun & A. Boudiba. (2019) Initiation de l’insulinothérapie avec un analogue d’une insuline prémix chez le diabétique de type 2 : rationnel et consensus. Médecine des Maladies Métaboliques 13, pages eS8-eS13.
Crossref
Crossref
Lixin Guo, Li Chen, Baocheng Chang, Liyong Yang, Yu Liu & Bo Feng. (2018) A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti. Diabetes, Obesity and Metabolism 20:12, pages 2740-2747.
Crossref
Crossref
Sanjay Kalra, Leszek Czupryniak, Gary Kilov, Roberta Lamptey, Ajay Kumar, A. G. Unnikrishnan, Aissa Boudiba, Mohamed Abid, Zhanay A. Akanov, Ali Latheef, Mustafa Araz, Ralph Audehm, Silver Bahendeka, Naby Balde, Sandeep Chaudhary, Chaicharn Deerochanawong, Olufemi Fasanmade, Hinde Iraqi, Tint Swe Latt, Jean Claude Mbanya, Joel Rodriguez-Saldana, Ko Seung Hyun, Zafar A. Latif, Maxim Lushchyk, Magdy Megallaa, Mohammed Wali Naseri, Nguyen Quang Bay, Kaushik Ramaiya, Hoosen Randeree, Syed Abbas Raza, Khalid Shaikh, Dina Shrestha, Eugene Sobngwi, Noel Somasundaram, Norlela Sukor & Rima Tan. (2018) Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. Diabetes Therapy 9:6, pages 2185-2199.
Crossref
Crossref
John A Tayek. (2018) Importance of fasting blood glucose goals in the management of type 2 diabetes mellitus: a review of the literature and a critical appraisal. Journal of Diabetes, Metabolic Disorders & Control 5:4, pages 113-117.
Crossref
Crossref
Daisuke Tsujino, Rimei Nishimura, Yoshiko Onda, Chiaki Seo, Kiyotaka Ando & Kazunori Utsunomiya. (2018) Biphasic insulin aspart-30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once-daily insulin regimens using continuous glucose monitoring. Journal of Diabetes Investigation 9:3, pages 573-578.
Crossref
Crossref
Bahendeka Silver, Kaushik Ramaiya, Swai Babu Andrew, Otieno Fredrick, Sarita Bajaj, Sanjay Kalra, Bavuma M. Charlotte, Karigire Claudine & Anthony Makhoba. (2018) EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Therapy 9:2, pages 449-492.
Crossref
Crossref
Sultan Linjawi, Byung-Wan Lee, Ömür Tabak, Susanna Lövdahl, Shanti Werther & Salahedeen Abusnana. (2017) A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes. Diabetes Therapy 9:1, pages 1-11.
Crossref
Crossref
Lawrence Blonde, Michel Marre, Maya Vincent, Sandrine Brette, Valerie Pilorget, Nicholas Danchin, Giacomo Vespasiani & Philip Home. (2017) Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. Diabetes Research and Clinical Practice 133, pages 150-158.
Crossref
Crossref
Marc Evans, Sayeed Achha & Cheryl Neslusan. (2017) Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes Therapy 8:5, pages 1175-1185.
Crossref
Crossref
Su-Yen Goh, Zanariah Hussein & Achmad Rudijanto. (2017) Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. Journal of Diabetes Investigation 8:5, pages 635-645.
Crossref
Crossref
S. Kumar, H. C. Jang, N. G. Demirağ, T. V. Skjøth, L. Endahl & B. Bode. (2017) Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabetic Medicine 34:2, pages 180-188.
Crossref
Crossref
Michelle Downie, Gary Kilov & Jencia Wong. (2016) Initiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix Regimens. Diabetes Therapy 7:4, pages 641-657.
Crossref
Crossref
Nick Freemantle, Engels Chou, Christian Frois, Daisy Zhuo, Walter Lehmacher, Aleksandra Vlajnic, Hongwei Wang, Hsing-wen Chung, Quanwu Zhang, Eric Wu & Charles Gerrits. (2016) Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open 6:2, pages e009421.
Crossref
Crossref
Martin J. Downes, Emilie K. Bettington, Jenny E. Gunton & Erika Turkstra. (2015) Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 3, pages e1461.
Crossref
Crossref
Ted Wu, Bryan Betty, Michelle Downie, Manish Khanolkar, Gary Kilov, Brandon Orr-Walker, Gordon Senator & Greg Fulcher. (2015) Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes. Diabetes Therapy 6:3, pages 273-287.
Crossref
Crossref
Przemyslaw Rys, Piotr Wojciechowski, Agnieszka Rogoz-Sitek, Grzegorz Niesyczyński, Joanna Lis, Albert Syta & Maciej T. Malecki. (2015) Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica 52:4, pages 649-662.
Crossref
Crossref
Philip D. Home, Marie-Paule Dain, Nick Freemantle, Ryuzo Kawamori, Martin Pfohl, Sandrine Brette, Valérie Pilorget, Werner A. Scherbaum, Giacomo Vespasiani, Maya Vincent & Beverley Balkau. (2015) Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Research and Clinical Practice 108:2, pages 350-359.
Crossref
Crossref
P. Rys, P. Wojciechowski, S. Siejka, P. Małecki, Ł. Hak & M. T. Malecki. (2014) A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis. International Journal of Clinical Practice 68:3, pages 304-313.
Crossref
Crossref
A. J. Garber. (2013) Treat‐to‐target trials: uses, interpretation and review of concepts. Diabetes, Obesity and Metabolism 16:3, pages 193-205.
Crossref
Crossref
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Hideaki Kaneto, Taka-aki Matsuoka & Iichiro Shimomura. (2014) Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocrine Journal 61:5, pages 447-456.
Crossref
Crossref
Elena Viktorovna Surkova. (2013) Ten years of NovoMix 30 in Russian and international clinical practice. Diabetes mellitus 16:4, pages 101-107.
Crossref
Crossref
Matthew D. Solomon, Sandeep Vijan, Felicia M. Forma, Ryan M. Conrad, Nicholas T. Summers & Darius N. Lakdawalla. (2013) The impact of insulin type on severe hypoglycaemia events requiring inpatient and emergency department care in patients with type 2 diabetes. Diabetes Research and Clinical Practice 102:3, pages 175-182.
Crossref
Crossref
Mohammad Ebrahim Khamseh, Jihad Haddad, Wenying Yang, Alexey Zilov, Ole Molskov Bech & Mohammad Imtiaz Hasan. (2013) Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis. Diabetes Therapy 4:2, pages 347-361.
Crossref
Crossref
Ofri Mosenzon & Itamar Raz. (2013) Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs. Diabetes Care 36:Supplement_2, pages S212-S218.
Crossref
Crossref
Alkassem Lezzar, Fatima Ayad, Amine Dahaoui, Abdellah Salah-Mansour & Abdesselam Yahia Berrouiguet. (2013) Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A1chieve study. Diabetes Research and Clinical Practice 101, pages S37-S44.
Crossref
Crossref
Mary Hines & Katherine W. Lyseng-Williamson. (2013) Biphasic insulin aspart 30: a guide to its use in diabetes mellitus. Drugs & Therapy Perspectives 29:5, pages 135-140.
Crossref
Crossref
Vito Borzì, Marian Benroubi, Janusz Gumprecht, Ryuzo Kawamori, Robert Ligthelm, Joseph Shaban, Siddharth Shah, Marina Shestakova, Yang Wenying & Paul Valensi. (2013) Predictors of postprandial blood glucose response to biphasic insulin analogue therapy. Primary Care Diabetes 7:1, pages 63-67.
Crossref
Crossref
Stéphanie Delestras, Matthieu Roustit, Pierrick Bedouch, Mélanie Minoves, Valérie Dobremez, Roseline Mazet, Audrey Lehmann, Magalie Baudrant & Benoît Allenet. (2013) Comparison between Two Generic Questionnaires to Assess Satisfaction with Medication in Chronic Diseases. PLoS ONE 8:2, pages e56247.
Crossref
Crossref
Andreas Liebl, Vinay Prusty, Paul Valensi, Ryuzo Kawamori, Jens Sandahl Christiansen, Andrew J. Palmer, Per Balschmidt, Robert Ligthelm & Viswanathan Mohan. (2012) Ten Years of Experience with Biphasic Insulin Aspart 30. Drugs 72:11, pages 1495-1520.
Crossref
Crossref
Yan Bi, Xiubin Li, Daizhi Yang, Yuantao Hao, Hua Liang, Dalong Zhu & Jianping Weng. (2012) Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses. Journal of Diabetes Investigation 3:3, pages 283-293.
Crossref
Crossref
A. E. Pontiroli, L. Miele & A. Morabito. (2012) Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:5, pages 433-446.
Crossref
Crossref
Allan Vaag & Sørens Lund. (2012) THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. European Journal of Endocrinology 166:2, pages 159-170.
Crossref
Crossref
C. V. Asche, B. Bode, A. K. Busk & S. R. Nair. (2011) The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 14:1, pages 47-57.
Crossref
Crossref
Jyrki K. Mäkelä, Christine Schmüser, Kari Askonen & Tero Saukkonen. (2012) Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland. Diabetes Research and Clinical Practice 95:1, pages 10-18.
Crossref
Crossref
M. John, S. Kalra, A.G. Unnikrishnan, B. Ganapathy, M.P. Baruah & R.K. Sahay. (2011) Recommendations for insulin initiation based on ethnicity. Medical Hypotheses 77:3, pages 460-461.
Crossref
Crossref
A N Oranskaia. (2011) Biphasic insulin analogs: their potential in the management of type 2 diabetes mellitus. Problems of Endocrinology 57:4, pages 48-55.
Crossref
Crossref
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini & Katherine Esposito. (2011) Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. Journal of Diabetes and its Complications 25:4, pages 275-281.
Crossref
Crossref
Katherine EspositoMaria Ida MaiorinoGiuseppe BellastellaPaolo ChiodiniDario Giugliano. (2011) Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials. Metabolic Syndrome and Related Disorders 9:3, pages 167-176.
Crossref
Crossref
D. Giugliano, M. Maiorino, G. Bellastella, P. Chiodini & K. Esposito. (2011) Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. International Journal of Clinical Practice 65:5, pages 602-612.
Crossref
Crossref
Dario Giugliano, Maria Ida Maiorino, Giusppe Bellastella, Paolo Chiodini & Katherine Esposito. (2011) Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice 92:1, pages 1-10.
Crossref
Crossref
Tim Heise, Cees J. Tack, Robert Cuddihy, Jaime Davidson, Didier Gouet, Andreas Liebl, Enrique Romero, Henriette Mersebach, Patrik Dykiel & Rolf Jorde. (2011) A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes. Diabetes Care 34:3, pages 669-674.
Crossref
Crossref
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Antonio Ceriello & Katherine Esposito. (2011) Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes. Diabetes Care 34:2, pages 510-517.
Crossref
Crossref
Takuma Narita, Takashi Goto, Yumi Suganuma, Mihoko Hosoba, Tsukasa Morii, Takehiro Sato, Hiroki Fujita, Takeshi Miura, Takashi Shimotomai, Yuichiro Yamada & Masafumi Kakei. (2011) Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study. Journal of Diabetes Investigation 2:1, pages 63-70.
Crossref
Crossref
Robert J. Ligthelm, Titus Gylvin, Tony DeLuzio & Philip Raskin. (2011) A Comparison of Twice-Daily Biphasic Insulin Aspart 70/30 and Once-Daily Insulin Glargine in Persons With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Therapy: A Randomized, Open-Label Study. Endocrine Practice 17:1, pages 41-50.
Crossref
Crossref
James L. Palmer, Amélie Beaudet, Jeremy White, Juliette Plun-Favreau & Jayne Smith-Palmer. (2010) Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 27:11, pages 814-827.
Crossref
Crossref
Ambika Gopalakrishnan UNNIKRISHNAN & Vinay PRUSTY. (2010) Response to Bloomgarden et al. Insulin treatment of type 2 diabetes: a clinical perspective. Journal of Diabetes 2:3, pages 136-137.
Crossref
Crossref
Sanjay Kalra, Teresa Plata-Que, Dileep Kumar, Malik Mumtaz, Flemming Søndergaard, Plamen Kozlovski & Wan Mohamad Wan Bebakar. (2010) Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Research and Clinical Practice 88:3, pages 282-288.
Crossref
Crossref
Marina Vladimirovna Shestakova & Akil Ballan. (2010) Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice. Diabetes mellitus 13:1, pages 92-100.
Crossref
Crossref